There is a need to improve accessibility of Bone Marrow Stem Cell Transplantation (BMSCT) for Sickle Cell Disease patients who are most likely to benefit from this treatment option.
1. Building a culture of trust between and among primary care providers, specialists, patients/families, and other stakeholders
2. Consensus building around BMSCT as an acceptable treatment alternative (as opposed to another research endeavor) for SCD among primary care providers, specialists, and patients/family in a population that has a history of being medically underserved and underrepresented in typical research agendas
3. It will be necessary to tailor message mapping and other communication strategies for all of the stakeholders
4. Risks and benefits are clearly communicated